Impact of gene polymorphisms on graft function in renal transplantation
| Project/Area Number |
20591540
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Clinical research Center, Chiba-East National Hospital, National Hospital Organization |
|---|
Principal Investigator |
SAIGO Kenichi Clinical research Center, Chiba-East National Hospital, National Hospital Organization, 臨床研究センター, 部長 (60323424)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MARUYAMA Michihiro 千葉東病院, 臨床研究センター, 室長 (40399754)
OHTSUKI Kazunori 千葉東病院, 臨床研究センター, 室長 (50399755)
KITAMURA Hiroshi 千葉東病院, 臨床研究センター, 室長 (40287701)
AKUTSU Naotake 千葉東病院, 臨床研究センター, 室長 (00344979)
KENMOCHI Takashi 千葉東病院, 臨床研究センター長 (50215133)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 移植・再生医療 / 遺伝子 / 薬剤反応性 / 外科 |
|---|
| Research Abstract |
Cyclosporine and tacrolimus are the substrates for Cytochrome P450 (CYP) 3A and P-glycoprotein, which are encoded by CYP3A gene and MDR1 gene. Several single nucleotide polymorphisms have been identified in these genes. In order to investigate the possible association of the CYP3A gene polymorphism and MDR1 gene polymorphism with graft function and rejection trough concentration and dose requirement in 128 renal transplant recipients.
100% and 96.8% of population showed a CYP3A4^*1B ^*1/^*1 and CPY3A4^*16 ^*1/^*1 genotype, while only 8% of population showed CYP3A5^*3 ^*1/^*1. For the SNP of MDR1 at exon21(2677G>(T,A)), wild type (G/G), hetero type (G/A, G/T), mutant type (T/T, A/A, A/T) were observed in 21 (16.5%), 51 (40.2%) and 55 (43.3%) cases and SNP of MDR1 at exon26(3435C>T), the CC,CT and TT genotypes were observed in39 (30.7%), 67 (52.8%) and 21 (16.5%) cases, respectively. There is no clear relationship between rejection and genotype. Some of our patients having CYP3A5^*1/^*1 genotype required a larger dose of tacrolimus to achieve the same concentrations as patients having other genotype.
|
Report
(4 results)
Research Products
(15 results)
